156 related articles for article (PubMed ID: 31043811)
21. Economic impact of preventing brain metastases with alectinib in ALK-positive non-small cell lung cancer.
Burudpakdee C; Wong W; Seetasith A; Corvino FA; Yeh W; Gubens M
Lung Cancer; 2018 May; 119():103-111. PubMed ID: 29656744
[TBL] [Abstract][Full Text] [Related]
22. Estimated direct costs of non-small cell lung cancer by stage at diagnosis and disease management phase: A whole-disease model.
Buja A; Rivera M; De Polo A; Brino ED; Marchetti M; Scioni M; Pasello G; Bortolami A; Rebba V; Schiavon M; Calabrese F; Mandoliti G; Baldo V; Conte P
Thorac Cancer; 2021 Jan; 12(1):13-20. PubMed ID: 33219738
[TBL] [Abstract][Full Text] [Related]
23. Thoracic Oncology Multidisciplinary Clinic Reduces Unnecessary Health Care Expenditure Used in the Workup of Patients With Non-small-cell Lung Cancer.
Voong KR; Liang OS; Dugan P; Torto D; Padula WV; Senter JP; Lang M; Hooker CM; Feliciano J; Broderick S; Yarmus L; Khanna K; Narang A; Hales RK
Clin Lung Cancer; 2019 Jul; 20(4):e430-e441. PubMed ID: 30956040
[TBL] [Abstract][Full Text] [Related]
24. Initial and Longitudinal Cost of Surgical Resection for Lung Cancer.
Cowper PA; Feng L; Kosinski AS; Tong BC; Habib RH; Putnam JB; Onaitis MW; Furnary AP; Wright CD; Jacobs JP; Fernandez FG
Ann Thorac Surg; 2021 Jun; 111(6):1827-1833. PubMed ID: 33031776
[TBL] [Abstract][Full Text] [Related]
25. Medical costs of lung cancer care in Japan during the first one or two years after initial diagnosis.
Awano N; Izumo T; Inomata M; Kuse N; Tone M; Takada K; Muto Y; Fujimoto K; Kimura H; Miyamoto S; Igarashi A; Kunitoh H
Jpn J Clin Oncol; 2021 Apr; 51(5):778-785. PubMed ID: 33506249
[TBL] [Abstract][Full Text] [Related]
26. Cost of combined modality interventions for stage III non-small-cell lung cancer.
Evans WK; Will BP; Berthelot JM; Earle CC
J Clin Oncol; 1997 Sep; 15(9):3038-48. PubMed ID: 9294466
[TBL] [Abstract][Full Text] [Related]
27. Management of febrile neutropenia--a German prospective hospital cost analysis in lymphoproliferative disorders, non-small cell lung cancer, and primary breast cancer.
Ihbe-Heffinger A; Paessens BJ; von Schilling C; Shlaen M; Gottschalk N; Berger K; Bernard R; Kiechle M; Peschel C; Jacobs VR
Onkologie; 2011; 34(5):241-6. PubMed ID: 21577029
[TBL] [Abstract][Full Text] [Related]
28. Unfavorable impact of cancer cachexia on activity of daily living and need for inpatient care in elderly patients with advanced non-small-cell lung cancer in Japan: a prospective longitudinal observational study.
Naito T; Okayama T; Aoyama T; Ohashi T; Masuda Y; Kimura M; Shiozaki H; Murakami H; Kenmotsu H; Taira T; Ono A; Wakuda K; Imai H; Oyakawa T; Ishii T; Omori S; Nakashima K; Endo M; Omae K; Mori K; Yamamoto N; Tanuma A; Takahashi T
BMC Cancer; 2017 Nov; 17(1):800. PubMed ID: 29183277
[TBL] [Abstract][Full Text] [Related]
29. Treatment cost of non-small cell lung cancer in three European countries: comparisons across France, Germany, and England using administrative databases.
McGuire A; Martin M; Lenz C; Sollano JA
J Med Econ; 2015; 18(7):525-32. PubMed ID: 25802950
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectivenes of paclitaxel plus cisplatin in advanced non-small-cell lung cancer.
Earle CC; Evans WK
Br J Cancer; 1999 May; 80(5-6):815-20. PubMed ID: 10360660
[TBL] [Abstract][Full Text] [Related]
31. Comparison of demographics, treatment patterns, health care utilization, and costs among elderly patients with extensive-stage small cell and metastatic non-small cell lung cancers.
Karve SJ; Price GL; Davis KL; Pohl GM; Smyth EN; Bowman L
BMC Health Serv Res; 2014 Nov; 14():555. PubMed ID: 25392276
[TBL] [Abstract][Full Text] [Related]
32. Real-world treatment patterns and costs in a US Medicare population with metastatic squamous non-small cell lung cancer.
Davis KL; Goyal RK; Able SL; Brown J; Li L; Kaye JA
Lung Cancer; 2015 Feb; 87(2):176-85. PubMed ID: 25532680
[TBL] [Abstract][Full Text] [Related]
33. Health care resource use among patients with advanced non-small cell lung cancer: the PIvOTAL retrospective observational study.
Lee DH; Isobe H; Wirtz H; Aleixo SB; Parente P; de Marinis F; Huang M; Arunachalam A; Kothari S; Cao X; Donnini N; Woodgate AM; de Castro J
BMC Health Serv Res; 2018 Mar; 18(1):147. PubMed ID: 29490654
[TBL] [Abstract][Full Text] [Related]
34. Costs of care associated with non-small-cell lung cancer in a commercially insured cohort.
Hillner BE; McDonald MK; Desch CE; Smith TJ; Penberthy LT; Maddox P; Retchin SM
J Clin Oncol; 1998 Apr; 16(4):1420-4. PubMed ID: 9552046
[TBL] [Abstract][Full Text] [Related]
35. Understanding total cost of care in advanced non-small cell lung cancer pre- and postapproval of immuno-oncology therapies.
Korytowsky B; Radtchenko J; Nwokeji ED; Tuell KW; Kish JK; Feinberg BA
Am J Manag Care; 2018 Oct; 24(20 Suppl):S439-S447. PubMed ID: 30362811
[TBL] [Abstract][Full Text] [Related]
36. A cost-effectiveness analysis of docetaxel in the second-line treatment of non-small cell lung cancer.
Holmes J; Dunlop D; Hemmett L; Sharplin P; Bose U
Pharmacoeconomics; 2004; 22(9):581-9. PubMed ID: 15209527
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness of continuation maintenance pemetrexed after cisplatin and pemetrexed chemotherapy for advanced nonsquamous non-small-cell lung cancer: estimates from the perspective of the Chinese health care system.
Zeng X; Peng L; Li J; Chen G; Tan C; Wang S; Wan X; Ouyang L; Zhao Z
Clin Ther; 2013 Jan; 35(1):54-65. PubMed ID: 23328269
[TBL] [Abstract][Full Text] [Related]
38. Estimation of lung cancer diagnosis and treatment costs based on a patient-level analysis in Catalonia (Spain).
Corral J; Espinàs JA; Cots F; Pareja L; Solà J; Font R; Borràs JM
BMC Health Serv Res; 2015 Feb; 15():70. PubMed ID: 25889153
[TBL] [Abstract][Full Text] [Related]
39. An economic analysis of sublobar resection versus thermal ablation for early-stage non-small-cell lung cancer.
Kwan SW; Mortell KE; Hippe DS; Brunner MC
J Vasc Interv Radiol; 2014 Oct; 25(10):1558-64; quiz 1565. PubMed ID: 25130308
[TBL] [Abstract][Full Text] [Related]
40. Hospitalization costs of lung cancer diagnosis in Turkey: Is there a difference between histological types and stages?
Türk M; Yıldırım F; Yurdakul AS; Öztürk C
Tuberk Toraks; 2016 Dec; 64(4):263-268. PubMed ID: 28393715
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]